This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PBH vs. ABT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why the Market Dipped But Abbott (ABT) Gained Today
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $128.47, representing a +2.4% change from its previous close.
Abbott Gains From Lingo CGM's Expansion on Android Platform
by Zacks Equity Research
ABT expands its Lingo biowearable to Android, broadening access to real-time glucose tracking and pushing continuous monitoring into mainstream wellness.
What Is Driving Hologic's Strength in the US Diagnostics Market?
by Moumi Mondal
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
by Moumi Mondal
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
Here's Why Abbott (ABT) Fell More Than Broader Market
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.
HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?
by Moumi Mondal
Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.
The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley
by Zacks Equity Research
HSBC, Abbott, Shell and Oak Valley feature in the latest Zacks Analyst Blog as analysts highlight operational resilience, strategic pivots and industry-specific challenges.
Top Analyst Reports for HSBC, Abbott & Shell
by Mark Vickery
HSBC's Asia pivot, Abbott's device momentum and Shell's resilient Q3 results headline today's standout analyst reports.